Countdown to 2030: eliminating hepatitis B disease, China.
Jue Liu, Wannian Liang, Wenzhan Jing...
https://pubmed.ncbi.nlm.nih.gov/30992636/Actively Recruiting
Led by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Updated on 2022-12-22
4500
Participants Needed
5
Research Sites
12 weeks
Total Duration
Chronic hepatitis B virus HBV infection is a significant global health concern. Researchers are investigating the clinical outcomes of patients with chronic hepatitis B CHB who are negative for hepatitis B e antigen HBeAg and fall into an indeterminate phase, meaning their blood test results do not clearly fit into the usual CHB phases. This study aims to understand the health progression of these patients, whose outcomes are not well known, which can help improve individual patient management. Participants are divided into two groups one group will be observed with regular monitoring every six months, and the other group will receive first-line antiviral treatments such as entecavir, tenofovir disoproxil fumarate, tenofovir alafenamide, tenofovir amibufenamide, or peginterferon. The study is a prospective, observational cohort design conducted across multiple centers, aiming to follow patients over a long period. During the study, participants will have regular assessments to track key outcomes including the occurrence of liver cancer hepatocellular carcinoma and the clearance rate of hepatitis B surface antigen HBsAg over 240 weeks about 4.5 years. Researchers will monitor liver health, viral levels, and other clinical markers to understand disease progression. The study is led by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School and will continue until May 2028.
CONDITIONS
Clinical Outcomes of HBeAg-negative CHB Patients With Indeterminate Phase
C
Chao Wu, M.D., Ph.D
R
Rui Huang, M.D., Ph.D
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 240 weeks
Participants are observed to monitor their health status and disease progression.
Visits every 6 months
Duration - Duration varies based on treatment
Participants who start antiviral treatment receive first-line antiviral medications and are monitored during therapy.
Visit schedule varies with treatment
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Jue Liu, Wannian Liang, Wenzhan Jing...
https://pubmed.ncbi.nlm.nih.gov/30992636/European Association for the Study of the Liver
https://pubmed.ncbi.nlm.nih.gov/28427875/Gwang Hyeon Choi, Gi-Ae Kim, Jonggi Choi...
https://pubmed.ncbi.nlm.nih.gov/31135074/M Bonacci, S Lens, Z Mariño...
https://pubmed.ncbi.nlm.nih.gov/29577350/Norah A Terrault, Anna S F Lok, Brian J McMahon...
https://pubmed.ncbi.nlm.nih.gov/29405329/Daniel Q Huang, Xiaohe Li, Michael H Le...
https://pubmed.ncbi.nlm.nih.gov/33465482/Chien-Jen Chen, Hwai-I Yang, Jun Su...
https://pubmed.ncbi.nlm.nih.gov/16391218/Kefang Yao, Jiacheng Liu, Jian Wang...
https://pubmed.ncbi.nlm.nih.gov/33797145/The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Lead Sponsor